You are browsing the Hong Kong website, Regulated by Hong Kong SFC (CE number: BJA907). Investment is risky and you must be cautious when entering the market.
歐康維視生物-B(01477.HK)擬收購在中國的埃美丁®及貝特舒®權利

格隆匯8月24日丨歐康維視生物-B(01477.HK)發佈公吿,2021年8月24日,公司全資附屬公司香港歐康維視與諾華訂立資產購買協議,據此,諾華同意於中國將轉移資產轉移予香港歐康維視;及向香港歐康維視授予許可資產在中國的許可,總代價為3500萬美元(相當於約2.269億人民幣),不包括任何增值税、商品及服務税、銷售税、使用税、物品税、消費税及其他類似的間接税(如適用)。

埃美丁®適用於治療過敏性結膜炎,暫時緩解其症狀及徵候。貝特舒®適用於降低由慢性開角型青光眼或高眼壓症引起的眼內壓的治療。收購埃美丁®及貝特舒®將增強集團治療過敏性結膜炎眼部瘙癢、開角型青光眼及高眼壓症的能力,並進一步豐富集團的現有產品組合。公司相信,收購事項將能夠把握收購事項在中國業務發展方面帶來的若干協同效應。需要該等產品治療過敏性結膜炎及高眼壓症患者及潛在患者的人數眾多,將為集團帶來重大市場機遇。

諾華歷史悠久,為一家備受認可且世界知名的生物製藥公司。憑藉該等產品的聲譽,公司相信集團眼科藥物的市場競爭力、品牌知名度及受歡迎程度將隨着收購事項而進一步提升,從而提升集團的整體銷售業績。公司亦相信,其將能夠把握收購事項在中國銷售渠道方面帶來的若干協同效應,包括但不限於市場滲透及擴充現有銷售渠道,此將有助進一步提升集團的品牌認知度以及營銷狀況。公司預期,通過收購事項引進先進的眼科生產技術,將進一步提升集團的生產水平及能力,為未來的海外擴展奠定堅實基礎。

Follow us
Find us on Facebook, Twitter , Instagram, and YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!
Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.
uSMART
Wealth Growth Made Easy
Open Account